Order tests and view results in one place

Expanding access to more EMRs

Genetic test ordering and results are now where you need them, when you need them. Myriad offers EMR integration, allowing providers and their patients instant access to important health information.

EMR integration benefits

Gain access to genetic testing within the EMR platform you use every day. Myriad’s EMR capabilities streamline ordering and results access, including the ability to conveniently share results with patients. Myriad offers native integration with most industry-leading EMRs, and can support customizable solutions for your EMR if needed.

Save staff time

Save time by directly ordering tests and viewing results within your EMR.

Increase result portability

Results are returned to your EMR and visible to providers across your organization.

Improve the patient experience

Share test and screen results with patients via your EMR’s patient portal.

Logos of Myriad Genetics and Epic

Epic and Myriad partnership

  • All Myriad offerings available in Epic Aura, founding member of the network
  • Epic-certified analysts and project managers to guide your organization’s adoption of Myriad tests in Aura
  • Utilizing Epic Aura allows bidirectional order and results integration easily with turbocharger build and an existing secure connection
Read the press release

Myriad results on Epic’s Care Everywhere network

In addition to our robust result report documents made available to providers and patients via Epic and MyChart, we provide Variant-Level Data that allows you to further your genomic care plans for patients using Epic Genomics. Additionally, we provide VCF data for your research needs.

ONCOEMR logoc

Flatiron Health and Myriad partnership

Myriad has partnered with Flatiron Health to provide an integration to OncoEMR®. By creating a streamlined, end-to-end workflow for germline testing in OncoEMR, clinicians will have access to the results they need at point-of-care, facilitating personalized treatment decisions for patients while reducing administrative burdens and improving turnaround times for results.

Read the press release

How to integrate Myriad into your EMR

Myriad makes the integration process simple for you. We assign a dedicated project team to work directly with your staff and the EMR vendor to ensure a smooth transition.

Step 1:
Notify Myriad
Let your sales rep know you’re interested in integrating with Myriad.

Step 2:
Provide information
We will collect information and submit a request to the Myriad Clinical Integrations team.

Step 3:
Plan and timeline
The Myriad team will coordinate with you and your sales rep to create a plan and timeline.

Myriad Genetics tests and screens

We offer industry-leading genetic insights with a seamless EMR experience. The following Myriad tests and screens are available as bidirectional interfaces (ordering + resulting) within your EMR platform.

MyRisk™ product signature
  • All-in-one personalized cancer risk assessment
  • Evaluates 63 genes associated with 11 different hereditary cancers
  • RiskScore® predicts a patient’s 5-year and lifetime risk of developing breast cancer
MyGeneHistory™ product signature
  • Online family history assessment identifies patients for genetic testing with MyRisk
  • Natively integrated with the athena, eCW, Epic, and NextGen-Office EMR platforms
  • Efficient end-to-end workflows for your staff and patients
Prequel®Prenatal Screen product signature
  • The only non-invasive prenatal screening (NIPS) that uses AMPLIFY® technology
  • 99.9% result delivery on the first draw at eight weeks1
  • Accessible and reliable for everybody, regardless of BMI, or ability to pay
Foresight® Carrier Screen product signature
  • Identify the 1 in 22 couples at risk for pregnancies with serious, prevalent, or clinically-actionable inherited conditions
  • 99% detection rate across ethnicities for the vast majority of the 269 genes on our panels2
GeneSight® Mental Health Medication Test product signature
  • Delivers genetic insights that can help inform your mental health treatment plans
  • Access to test significantly improved remission and response rates compared to treatment as usual3
  • Ordered by tens of thousands of clinicians for 2MM+ patients
View integration info sheet
Precise Tumor product signature
  • Identifies actionable genomic variants and biomarkers associated with FDA-approved therapies
MyChoice CDx product signature
  • Identifies HRD status to inform treatment strategies
FOLR1/FRa product signature
  • IHC Test to identify patients with ovarian cancer who may qualify for treatment with mirvetuximab
FirstGene product signature

Coming soon

Precise MRD product signature

Coming soon

Prolaris product signature

Coming soon

Coming soon

FirstGene®
Precise MRD®
Prolaris®

Streamline your EMR experience

Introducing an easier way to test, report and share. Simplify your testing workflow with Myriad’s EMR integrations.











You agree to be contacted with newsletters, marketing or promotional materials and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in any email we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Policy.

Hidden Fields











Hidden test fields



References
  1. Welker et al. High-throughput fetal fraction amplification increases analytical performance of noninvasive prenatal screening. Genet Med 23, 443–450 (2021)
  2. Myriad Genetics. Data on file. https://myriad-library.s3.amazonaws.com/mwh/disease-detection-fact-sheet.pdf
  3. Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on Clinical Outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research. 2019;111:59-67. doi:10.1016/j.jpsychires.2019.01.003; Oslin DW, Lynch KG, Shih M-C, et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder. JAMA. 2022;328(2):151. doi:10.1001/jama.2022.9805; Brown L, Vranjkovic O, Li J, et al. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: A meta-analysis. Pharmacogenomics. 2020;21(8):559-569. doi:10.2217/pgs-2019-0157

Locations

United States
Europe
Japan